NAD Augmentation in Diabetes Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 156 participants.

Also called NCT05759468

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05759468
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05759468. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-13 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NAD Augmentation in Diabetes Kidney Disease
Acronym
DKD
Condition
Type2diabetes
Condition
Diabetic Kidney Disease
Intervention (Drug)
Investigational Product - MIB 626
Intervention (Drug)
Placebo
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
Boston Medical Center (class: other)

Record details

Record id
cardio:ct-nct05759468
Content hash
876b8d243adcd7efadc9f0ae4dd0645b2a29701900bf7ed458d647e7f2a174c7